Delandistrogene Moxeparvovec: First Approval

Area of Science:

• Gene Therapy
• Neuromuscular Disorders
• Molecular Biology

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration.
• Current treatments for DMD focus on symptom management, with limited options for addressing the underlying genetic cause.
• Delandistrogene moxeparvovec represents a novel therapeutic approach utilizing gene therapy to target the root cause of DMD.

Purpose of the Study:

• To summarize the developmental milestones of delandistrogene moxeparvovec.
• To highlight its approval as the first gene therapy for Duchenne muscular dystrophy in the USA.
• To detail the indication and dosage for this groundbreaking treatment.

Main Methods:

• Development of an adeno-associated virus (AAV) vector to deliver a micro-dystrophin gene.
• Clinical trials to assess the safety and efficacy of delandistrogene moxeparvovec.
• Regulatory review process leading to FDA approval.

Main Results:

• Delandistrogene moxeparvovec received FDA approval in June 2023 via the Accelerated Approval pathway.
• It is indicated for ambulatory pediatric patients aged 4-5 years with DMD and a confirmed dystrophin gene mutation.
• The approved dose is 1.33 × 10^14 vector genomes/kg or 10 mL/kg body weight via a single intravenous infusion.

Conclusions:

• Delandistrogene moxeparvovec marks a significant advancement in DMD treatment, offering a gene therapy option.
• This approval signifies a major milestone in the therapeutic landscape for Duchenne muscular dystrophy.
• Ongoing clinical development in the EU and Japan suggests broader future accessibility.